Announcement e-learning developments prostate cancer
Reimbursement for XTANDI™ (enzalutamide) for patient high-risk nmCRPC*1
www.bms.com/be www.immunooncology.be/nl/home www.immunoscienceacademy.be
www.pfizer.be www.pfizerpro.be
www.rochepro.be www.roche.be www.samenverder.be www.avancerensemble.be
